NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $6.14 +0.85 (+16.07%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.16 +0.03 (+0.41%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verastem Stock (NASDAQ:VSTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verastem alerts:Sign Up Key Stats Today's Range$5.15▼$6.2950-Day Range$4.15▼$8.5252-Week Range$2.10▼$9.10Volume6.75 million shsAverage Volume2.17 million shsMarket Capitalization$337.39 millionP/E RatioN/ADividend YieldN/APrice Target$13.38Consensus RatingBuy Company Overview Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. Read More Verastem Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreVSTM MarketRank™: Verastem scored higher than 71% of companies evaluated by MarketBeat, and ranked 317th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has only been the subject of 2 research reports in the past 90 days.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($3.02) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Verastem's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.70% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently decreased by 99.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.70% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently decreased by 99.70%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.89 News SentimentVerastem has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Verastem this week, compared to 4 articles on an average week.Search InterestOnly 14 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows1 people have added Verastem to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $693,033.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Stock News HeadlinesVerastem Oncology gets FDA fast track status for cancer drugJuly 24 at 12:01 PM | msn.comVerastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic CancerJuly 24 at 12:01 PM | finance.yahoo.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 27 at 2:00 AM | Priority Gold (Ad)Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer TreatmentJuly 18, 2025 | tipranks.comVerastem: The Market Is Ignoring The ProgressJuly 16, 2025 | seekingalpha.comVerastem stock rises after LGSOC treatment data published in medical ...July 13, 2025 | investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...July 11, 2025 | gurufocus.comVerastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock NewsJuly 11, 2025 | gurufocus.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $5.17 on January 1st, 2025. Since then, VSTM stock has increased by 18.8% and is now trading at $6.14. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.24. When did Verastem's stock split? Verastem's stock reverse split on Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings5/13/2025Today7/26/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Verastem$13.38 High Price Target$20.00 Low Price Target$8.00 Potential Upside/Downside+117.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.64 million Net MarginsN/A Pretax Margin-1,486.92% Return on Equity-2,003.62% Return on Assets-127.97% Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio3.50 Sales & Book Value Annual Sales$10 thousand Price / Sales33,739.30 Cash FlowN/A Price / Cash FlowN/A Book Value($0.65) per share Price / Book-9.45Miscellaneous Outstanding Shares54,950,000Free Float53,795,000Market Cap$337.39 million OptionableOptionable Beta0.71 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:VSTM) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.